Health

Device That Uses Light and Sound May Slow Alzheimer’s Symptoms in Some Patients

An experimental device using light and sound slowed cognitive decline in patients with mild Alzheimer’s disease, according to trial results announced Monday at a scientific conference in Boston. The device, called Spectris, uses gamma wave therapy at 40 hertz, but the benefit was observed only in those with mild cognitive impairment, not moderate cases.

The trial included more than 670 participants who used the device for 50 minutes a day, six days a week over the course of a year, according to Cognito Therapeutics, the Cambridge biotech company that announced the findings.

Using one common measure of cognitive functioning, the device slowed decline by 56 percent; against another measurement, it was 47 percent effective, the company said.

The device, called Spectris, is non-invasive and designed for home use. It resembles a pair of sunglasses attached to headphones and delivers gamma wave therapy at 40 hertz, based on research by MIT scientists. Gamma waves are electrical signals brain cells produce during learning or concentration, according to the company.

Christian Howell, Cognito’s CEO, said the technology stimulates the brain at 40 hertz, which can drive biological processes critical to preserving brain structure and function. He said the device works by “bypassing that network dysfunction,” aiming to maintain healthy brain activity even when amyloid and tau proteins are present. Howell noted the technology does not clear amyloid plaques or tau from people.

The trial was designed to measure efficacy in people with mild to moderate Alzheimer’s disease. It did not show a treatment effect in participants with moderate cases, according to the company.

“The potential implications are massive,” Howell said. “Many people have the ability to bring this into their lives and really positively impact what they’re experiencing.”

The results have not yet been peer-reviewed. Cognito plans to submit the findings to the New England Journal of Medicine, the company said. It also plans to petition the Food and Drug Administration for approval next year and could receive authorization by the end of 2027, according to Howell.

Heather Snyder, senior vice president of medical and scientific relations at the Alzheimer’s Association, offered a cautious assessment of the findings.

“There’s a hint that there may be something there, but it’s unproven and needs to be verified,” Snyder said.

MIT neuroscientists Li-Huei Tsai and Ed Boyden first discovered in 2016 that gamma brainwaves had potential as a therapy. They co-founded Cognito and remain scientific advisors. The researchers learned they could trigger gamma waves in mice using light and sound stimulation, observing that the brainwaves could clear mouse brains of amyloid plaques.

“It’s incredible,” Tsai said. “With the mild population of Alzheimer’s disease, the treatment showed such a large effect.”

The results come as two approved drugs for Alzheimer’s, Leqembi and Kisunla, are on the market. Those drugs work by targeting amyloid plaques and have been shown to slow cognitive decline by about 20 to 30 percent, according to trial data. They carry side effects, including temporary brain swelling.

The findings were presented Monday at a scientific conference in Boston. This is a developing story and will be updated.

.

Evan Vega

Evan Vega is a national affairs correspondent covering politics, public health, and regional policy across multiple states. His reporting connects statehouse developments to their real-world impact on communities. Evan has covered three presidential cycles and specializes in the intersection of state governance and federal policy.